Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dual antiplatelet therapy is recommended after coronary stenting to prevent thrombotic complications, yet the benefits and risks of treatment beyond 1 year are uncertain. METHODS: Patients were enrolled after they had undergone a coronary stent procedure in which a drug-eluting stent was placed. After 12 months of treatment with a thienopyridine drug (clopidogrel or prasugrel) and aspirin, patients were randomly assigned to continue receiving thienopyridine treatment or to receive placebo for another 18 months; all patients continued receiving aspirin. The coprimary efficacy end points were stent thrombosis and major adverse cardiovascular and cerebrovascular events (a composite of death, myocardial infarction, or stroke) during the period from 12 to 30 months. The primary safety end point was moderate or severe bleeding. RESULTS: A total of 9961 patients were randomly assigned to continue thienopyridine treatment or to receive placebo. Continued treatment with thienopyridine, as compared with placebo, reduced the rates of stent thrombosis (0.4% vs. 1.4%; hazard ratio, 0.29 [95% confidence interval {CI}, 0.17 to 0.48]; P<0.001) and major adverse cardiovascular and cerebrovascular events (4.3% vs. 5.9%; hazard ratio, 0.71 [95% CI, 0.59 to 0.85]; P<0.001). The rate of myocardial infarction was lower with thienopyridine treatment than with placebo (2.1% vs. 4.1%; hazard ratio, 0.47; P<0.001). The rate of death from any cause was 2.0% in the group that continued thienopyridine therapy and 1.5% in the placebo group (hazard ratio, 1.36 [95% CI, 1.00 to 1.85]; P=0.05). The rate of moderate or severe bleeding was increased with continued thienopyridine treatment (2.5% vs. 1.6%, P=0.001). An elevated risk of stent thrombosis and myocardial infarction was observed in both groups during the 3 months after discontinuation of thienopyridine treatment. CONCLUSIONS: Dual antiplatelet therapy beyond 1 year after placement of a drug-eluting stent, as compared with aspirin therapy alone, significantly reduced the risks of stent thrombosis and major adverse cardiovascular and cerebrovascular events but was associated with an increased risk of bleeding. (Funded by a consortium of eight device and drug manufacturers and others; DAPT ClinicalTrials.gov number, NCT00977938.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, the reporting and interpretation of the risk of all-cause mortality in the DAPT (dual antiplatelet therapy) study randomizing 9,961 patients to continue DAPT beyond 1 y after stent placement or receive a placebo for 30 mo, raised some concerns (24, 25).”
From Misrepresentation and distortion of research in biomedical literature (2018) · cites this paper as [24]
In the citing paper
“Large observational studies or head-to-head RCTs show similar rates of gastrointestinal and non-gastrointestinal major bleeding for single antiplatelet therapy (SAPT) with low-dose ASA or a P2Y 12 inhibitor (clopidogrel or ticagrelor).”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [337]
In the citing paper
“Regarding CV safety, the composite of MI, stroke, CV death, CHD, and acute limb ischaemia was similar between pantoprazole and placebo, as was the rate of new-onset diabetes.”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [337]
In the citing paper
“Thus, gastrointestinal mucosal bleeding appears to be due to pre-existing mucosal lesions associated with defective primary haemostasis secondary to platelet inhibition, rather than with a specific antiplatelet drug.”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [337]
In the citing paper
“Combined antithrombotic drugs, while effective, increase major bleeding risk.337,338”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [337]
Citations
Cites
Statistical Analysis With Missing Data
Lahiff, M., Little, R. J. A., & Rubin, D. B. (1989) · Journal of the American Statistical Association · doi:10.2307/2289883 · Cited by 17,265
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Beaton, A. Z., Boehme, A. K., Buxton, A. E., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001123 · Cited by 8,300
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Self-citationPrasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
Self-citation(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions
Cutlip, D. E., Windecker, S., Mehran, R., Boam, A., Cohen, D. J., van Es, G.-A., Gabriel Steg, P., Morel, M.-A., Mauri, L., Vranckx, P., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.685313 · Cited by 5,497
Self-citationHeart Disease and Stroke Statistics—2013 Update: A Report From the American Heart Association
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., Fox, C. S., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31828124ad · Cited by 5,292
Mehran, R., Rao, S. V., Bhatt, D. L., Gibson, C. M., Caixeta, A., Eikelboom, J., Kaul, S., Wiviott, S. D., Menon, V., Nikolsky, E., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.009449 · Cited by 4,476
Self-citation(2014) · European Heart Journal · doi:10.1093/eurheartj/ehu278 · Cited by 4,314
Research works printed but not linked: 1
- Feres F, 2013, JAMA, 310, 2510
Cited by
Items 101–200 of 1,001
Long-Term Use of Cardiovascular Drugs
Rossello, X., Pocock, S. J., & Julian, D. G. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.07.018 · Cited by 166
Bonaca, M. P., Bhatt, D. L., Steg, P. G., Storey, R. F., Cohen, M., Im, K., Oude Ophuis, T., Budaj, A., Goto, S., López-Sendón, J., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv531 · Cited by 166
Self-citationChallenges in secondary prevention after acute myocardial infarction: A call for action
Piepoli, M. F., Corrà, U., Dendale, P., Frederix, I., Prescott, E., Schmid, J. P., Cupples, M., Deaton, C., Doherty, P., Giannuzzi, P., et al. (2016) · European Journal of Preventive Cardiology · doi:10.1177/2047487316663873 · Cited by 165
F. Piepoli, M. (2017) · International Journal of Behavioral Medicine · doi:10.1007/s12529-016-9583-6 · Cited by 162
Bleeding avoidance strategies in percutaneous coronary intervention
Capodanno, D., Bhatt, D. L., Gibson, C. M., James, S., Kimura, T., Mehran, R., Rao, S. V., Steg, P. G., Urban, P., Valgimigli, M., et al. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00598-1 · Cited by 162
Self-citationSex differences in mechanisms, presentation and management of ischaemic heart disease
Crea, F., Battipaglia, I., & Andreotti, F. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.04.802 · Cited by 159
Frailty and Cardiovascular Health
James, K., Jamil, Y., Kumar, M., Kwak, M. J., Nanna, M. G., Qazi, S., Troy, A. L., Butt, J. H., Damluji, A. A., Forman, D. E., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.031736 · Cited by 165
“66 Adding to the argument for shorter-duration DAPT, a meta-analysis of nearly 6000 participants showed that shorter DAPT (3–6 months versus 12 months) may not increase the risk of ischemic events but does result in favorable bleeding outcomes in adults 65 years and older.”
Ariotti, S., Adamo, M., Costa, F., Patialiakas, A., Briguori, C., Thury, A., Colangelo, S., Campo, G., Tebaldi, M., Ungi, I., et al. (2016) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2015.11.015 · Cited by 158
Palmerini, T., Reggiani, M. L. B., Riva, D. D., Romanello, M., Feres, F., Abizaid, A., Gilard, M., Morice, M., Valgimigli, M., Hong, M., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.02.029 · Cited by 158
Self-citationTicagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting
Franzone, A., McFadden, E. P., Leonardi, S., Piccolo, R., Vranckx, P., Serruys, P. W. J. C., Benit, E., Liebetrau, C., Janssens, L., Ferrario, M., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.08.1038 · Cited by 163
Self-citationHan, Y., Xu, B., Xu, K., Guan, C., Jing, Q., Zheng, Q., Li, X., Zhao, X., Wang, H., Zhao, X., et al. (2016) · Circulation: Cardiovascular Interventions · doi:10.1161/circinterventions.115.003145 · Cited by 153
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M. T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · Kardiologia Polska · doi:10.5603/kp.2016.0120 · Cited by 178
2020 Clinical practice guidelines for Acute coronary syndrome without ST segment elevation
Барбараш, О. Л., Duplyakov, D. V., Zateischikov, D. A., Панченко, Е. П., Shakhnovich, R. M., Yavelov, I. S., Yakovlev, A. N., Sa, A., Alekyan, B. G., Викторович, А. М., et al. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2021-4449 · Cited by 149
From Atherosclerotic Plaque to Myocardial Infarction—The Leading Cause of Coronary Artery Occlusion
Młynarska, E., Czarnik, W., Fularski, P., Hajdys, J., Majchrowicz, G., Stabrawa, M., Rysz, J., & Franczyk, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137295 · Cited by 191
“In contrast, prolonged DAPT should be considered in patients at high thrombotic risk and without an increased risk of major or life-threatening bleeding [141].”
BackgroundNatsuaki, M., Morimoto, T., Shiomi, H., Yamaji, K., Watanabe, H., Shizuta, S., Kato, T., Andò, K., Nakagawa, Y., Furukawa, Y., et al. (2019) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.119.008307 · Cited by 148
CHAITMAN, B. R., Alexander, K. P., Cyr, D. D., Berger, J. S., Reynolds, H. R., Bangalore, S., Boden, W. E., Lópes, R. D., Demkow, M., Perna, G. P., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.047987 · Cited by 148
O’Donoghue, M. L., Murphy, S. A., & Sabatine, M. S. (2020) · Circulation · doi:10.1161/circulationaha.120.046251 · Cited by 145
The Primary Outcome Is Positive — Is That Good Enough?
Pocock, S. J., & Stone, G. W. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1601511 · Cited by 142
Current concepts and novel targets for antiplatelet therapy
Gawaz, M., Geisler, T., & Borst, O. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00854-6 · Cited by 148
Roffi, M., Patrono, C., Collet, J., Mueller, C. E., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2015) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2015.10.009 · Cited by 148
Mathews, R., Wang, T. Y., Honeycutt, E. F., Henry, T. D., Zettler, M. E., Chang, M., Fonarow, G. C., & Peterson, E. D. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.03.019 · Cited by 152
Hong, S., Shin, D., Kim, J., Kim, B., Ko, Y., Choi, D., Her, A., Kim, Y. H., Jang, Y., & Hong, M. (2016) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2016.04.036 · Cited by 139
“On the contrary, the randomized study with the largest sample size (n 1⁄4 9,961) revealed that more favorable clinical outcomes occurred in patients who received DAPT beyond 1 year, even after implantation of a new-generation DES (14).”
BackgroundResultSchiele, F., Gale, C. P., Bonnefoy, E., Capuano, F., Claeys, M. J., Danchin, N., Fox, K. A., Huber, K., Iakobishvili, Z., Lettino, M., et al. (2017) · European Heart Journal: Acute Cardiovascular Care · doi:10.1177/2048872616643053 · Cited by 132
Yeh, R. W., Kereiakes, D. J., Steg, P. G., Cutlip, D. E., Croce, K., Massaro, J. M., & Mauri, L. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.09.011 · Cited by 136
“The DAPT Study, as previously described (1,5), was a double-blind, international, multicenter, randomized, placebo-controlled trial that compared the benefits and risks of 30 months versus 12 months of thienopyridine therapy (clopidogrel or prasugrel) when prescribed in addition to aspirin following coronary stenting…”
Self-citationPlatelet-Cancer Interplay: Molecular Mechanisms and New Therapeutic Avenues
Braun, A., Anders, H., Gudermann, T. W., & Mammadova‐Bach, E. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.665534 · Cited by 142
Coronary Atherosclerosis: Pathophysiologic Basis for Diagnosis and Management
Boudoulas, K. D., Triposkiadis, F. K., Geleris, P., & Boudoulas, H. K. (2016) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2016.04.003 · Cited by 152
Causes of Death Following PCI Versus CABG in Complex CAD
Milojevic, M., Head, S. J., Parasca, C. A., Serruys, P. W. J. C., Mohr, F. W., Morice, M., Mack, M. J., Ståhle, E., Feldman, T. E., Dawkins, K. D., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.10.043 · Cited by 131
“The impact of prolonged use and the exact duration of dual antiplatelet therapy on ischemic events remain topics of debate (23,24).”
BackgroundSelf-citationBehan, M., Holm, N. R., de Belder, A., Cockburn, J., Ērglis, A., Curzen, N. P., Niemelä, M. J., Oldroyd, K. G., Kervinen, K., Kumsārs, I., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw170 · Cited by 128
Atherothrombosis and Oxidative Stress: Mechanisms and Management in Elderly
Violi, F., Loffredo, L., Carnevale, R., Pignatelli, P., & Pastori, D. (2017) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6963 · Cited by 118
“The study showed a lower efficacy of antiplatelet therapy in reducing CVEs and CD in patients <75 (n = 8929) versus ‡75 years (n = 1032) (230).”
Yin, S., Xu, P., Wang, B., Lu, Y., Wu, Q., Zhou, M.-L., Wu, J., Cai, J., Sun, X., & Yuan, H. (2019) · BMJ · doi:10.1136/bmj.l2222 · Cited by 127
Parasca, C. A., Head, S. J., Milojevic, M., Mack, M. J., Serruys, P. W. J. C., Morice, M., Mohr, F. W., Feldman, T. E., Colombo, A., Dawkins, K. D., et al. (2016) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2016.09.044 · Cited by 126
“Furthermore, in alignment with randomized trials evaluating post-PCI antiplatelet therapy and current guidelines, we found that nonuse of acetylsalicylic acid or thienopyridine predicted repeat revascularization (28,29), and medical therapy was also a predictor of worse long-term outcomes (30).”
MethodSelf-citation2-Year Outcomes of High Bleeding Risk Patients After Polymer-Free Drug-Coated Stents
Garot, P., Morice, M., Tresukosol, D., Pocock, S., Meredith, I. T., Abizaid, A., Carrié, D., Naber, C. K., Íñiguez, A., Talwar, S., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.10.009 · Cited by 125
Mitsis, A., & Gragnano, F. (2020) · Current Cardiology Reviews · doi:10.2174/1573403x16999201210195702 · Cited by 138
Patti, G., Cavallari, I., Andreotti, F., Calabrò, P., Cirillo, P. L., Denas, G., Galli, M., Golia, E., Maddaloni, E., Marcucci, R., et al. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0080-2 · Cited by 128
Baber, U., Dangas, G., Cohen, D. J., Gibson, C. M., Mehta, S. R., Angiolillo, D. J., Pocock, S., Krucoff, M. W., Kastrati, A., Ohman, E. M., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.09.006 · Cited by 125
Self-citationNakamura, M., Iijima, R., Ako, J., Shinke, T., Okada, H., Ito, Y., Andò, K., Anzai, H., Tanaka, H., Ueda, Y., et al. (2017) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2017.04.019 · Cited by 123
“However, it is not in agreement with the results of the DAPT trial or with the findings of meta-analysis (9,20).”
BackgroundResultEvaluation and Management of Patients With Stable Angina: Beyond the Ischemia Paradigm
Ferraro, R., Latina, J. M., Alfaddagh, A., Michos, E. D., Blaha, M. J., Jones, S. R., Sharma, G. V., Trost, J. C., Boden, W. E., Weintraub, W. S., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.08.078 · Cited by 131
P2Y12 Inhibition beyond Thrombosis: Effects on Inflammation
Mansour, A., Bachelot‐Loza, C., Nesseler, N., Gaussem, P., & Gouin‐Thibault, I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041391 · Cited by 113
Duration of Dual Antiplatelet Therapy After Coronary Stenting
Montalescot, G., Brieger, D. B., Dalby, A. J., Park, S., & Mehran, R. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.05.053 · Cited by 115
Choi, K. H., Park, Y. H., Lee, J., Jeong, J., Kim, C. J., Yun, K. H., Lee, H. C., Chang, K., Park, M., Bae, J., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00449-0 · Cited by 115
“25 Furthermore, an increased risk of death from any cause with clopidogrel treatment, a concern raised by previous studies, 7,15 was not observed in this trial.”
Vranckx, P., Valgimigli, M., Windecker, S., Steg, P. G., Hamm, C. W., Jüni, P., García‐García, H. M., van Es, G., & Serruys, P. W. J. C. (2016) · EuroIntervention · doi:10.4244/eijy15m11_07 · Cited by 109
Self-citationMedical Therapy for Long-Term Prevention of Atherothrombosis Following an Acute Coronary Syndrome
Gallone, G., Baldetti, L., Pagnesi, M., Latib, A., Colombo, A., Libby, P., & Giannini, F. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.09.052 · Cited by 116
Antiplatelet therapy in cardiovascular disease: Current status and future directions
Passacquale, G., Sharma, P., Perera, D., & Ferro, A. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15221 · Cited by 117
Platelets control liver tumor growth through P2Y12-dependent CD40L release in NAFLD
Ma, C., Fu, Q., Diggs, L. P., McVey, J. C., McCallen, J., Wabitsch, S., Ruf, B., Brown, Z. J., Heinrich, B., Zhang, Q., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.08.004 · Cited by 106
Piccolo, R., Oliva, A., Avvedimento, M., Franzone, A., Windecker, S., Valgimigli, M., Esposito, G., & Jüni, P. (2021) · EuroIntervention · doi:10.4244/eij-d-20-01197 · Cited by 105
Cao, D., Chandiramani, R., Chiarito, M., Claessen, B. E. P. M., & Mehran, R. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa824 · Cited by 105
Bittl, J. A., & He, Y. (2017) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.117.003563 · Cited by 111
Bonaca, M. P., Bhatt, D. L., Ophuis, T. O., Steg, P. G., Storey, R. F., Cohen, M. C., Kuder, J., Im, K., Magnani, G., Budaj, A., et al. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.1017 · Cited by 100
Self-citationStone, G. W., Hochman, J. S., Williams, D. O., Boden, W. E., Ferguson, T. B., Harrington, R. A., & Maron, D. J. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.09.056 · Cited by 107
Kereiakes, D. J., Yeh, R. W., Massaro, J. M., Driscoll-Shempp, P., Cutlip, D. E., Steg, P. G., Gershlick, A. H., Darius, H., Meredith, I. T., Ormiston, J., et al. (2015) · JAMA · doi:10.1001/jama.2015.1671 · Cited by 94
Self-citationFranzone, A., Piccolo, R., Gargiulo, G., Ariotti, S., Marino, M., Santucci, A., Baldo, A., Magnani, G., Moschovitis, A., Windecker, S., et al. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.2811 · Cited by 93
Валерьевич, А. О., HARUTYUNYAN, G., Duplyakov, D. V., Константинова, Е. В., Konstantinova, N. N., Shakhnovich, R. M., Yavelov, I. S., Yakovlev, A. N., Sa, A., Alekyan, B. G., et al. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6306 · Cited by 100
A Critical Appraisal of Aspirin in Secondary Prevention: Is Less More?
Gargiulo, G., Windecker, S., Vranckx, P., Gibson, C. M., Mehran, R., & Valgimigli, M. (2016) · Circulation · doi:10.1161/circulationaha.116.023952 · Cited by 97
Abu‐Assi, E., López-López, A., Salvado, V. G., Diéguez, A. R., Peña, C., Bouzas‐Cruz, N., Raposeiras‐Roubín, S., Abumuaileq, R. R.-Y., García‐Acuña, J. M., & González‐Juanatey, J. R. (2015) · Revista Española de Cardiología · doi:10.1016/j.recesp.2015.06.016 · Cited by 94
Platelets and Metastasis: New Implications of an Old Interplay
Lucotti, S., & Muschel, R. J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01350 · Cited by 96
“Despite promising preclinical data, the ADP P2Y12 receptor antagonist prasugrel (TRITON-TIMI 38 trial) (281, 282) and the P2Y12 inhibitors thienopyridines (clopidogrel and prasugrel) (283) increased the incidence of newly diagnosed solid cancers and the risk of cancerrelated death.”
BackgroundDAPT Score Utility for Risk Prediction in Patients With or Without Previous Myocardial Infarction
Kereiakes, D. J., Yeh, R. W., Massaro, J. M., Cutlip, D. E., Steg, P. G., Wiviott, S. D., & Mauri, L. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.485 · Cited by 93
Self-citationInvasive FFR and Noninvasive CFR in the Evaluation of Ischemia
Johnson, N. P., Gould, K. L., Carli, M. F. D., & Taqueti, V. R. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.584 · Cited by 100
Diabetes Mellitus and Acute Myocardial Infarction: Impact on Short and Long-Term Mortality
Milazzo, V., Cosentino, N., Genovese, S., Campodonico, J., Mazza, M., Metrio, M. D., & Marenzi, G. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_481 · Cited by 98
Angiolillo, D. J., Goodman, S. G., Bhatt, D. L., Eikelboom, J. W., Price, M. J., Moliterno, D. J., Cannon, C. P., Tanguay, J., Granger, C. B., Mauri, L., et al. (2016) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.116.004395 · Cited by 94
Self-citationLópes, R. D., Vora, A. N., Liaw, D., Granger, C. B., Darius, H., Goodman, S. G., Mehran, R., Windecker, S., & Alexander, J. H. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.03.001 · Cited by 94
Fanaroff, A. C., Cyr, D. D., Neely, M. L., Bakal, J. A., White, H. D., Fox, K. A. A., Armstrong, P. W., Lópes, R. D., Ohman, E. M., & Roe, M. T. (2018) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.118.004755 · Cited by 93
Guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Bénétos, A., Biffi, A., Boavida, J. M., Capodanno, D., et al. (2022) · Revista Española de Cardiología · doi:10.1016/j.recesp.2021.10.016 · Cited by 124
Valgimigli, M., Smits, P. C., Frigoli, E., Bongiovanni, D., Tijssen, J. G. P., Hovasse, T., Mafragi, A., Ruifrok, W. T., Karageorgiev, D., Aminian, A., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac284 · Cited by 90
Classification of Platelet Aggregates by Agonist Type
Zhou, Y., Yasumoto, A., Lei, C., Huang, C., Kobayashi, H., Wu, Y., Yan, S., Sun, C., Yatomi, Y., & Goda, K. (2019) · eLife · doi:10.7554/elife.52938 · Cited by 90
“, aspirin or thienopyridines) for antiplatelet therapy (Mauri et al., 2014; Roe et al., 2012), the gold standard of the treatment and prevention of atherothrombosis (e.”
BackgroundManagement of myocardial revascularisation failure: an expert consensus document of the EAPCI
Stefanini, G. G., Alfonso, F., Barbato, E., Byrne, R. A., Capodanno, D., Colleran, R., Escaned, J., Giacoppo, D., Kunadian, V., Lansky, A. J., et al. (2020) · EuroIntervention · doi:10.4244/eij-d-20-00487 · Cited by 89
Routine Functional Testing or Standard Care in High-Risk Patients after PCI
Park, D., Kang, D., Ahn, J., Yun, S., Yoon, Y., Hur, S., Lee, C. H., Kim, W., Kang, S. H., Park, C. S., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2208335 · Cited by 91
Costa, F., Vranckx, P., Leonardi, S., Moscarella, E., Andò, G., Calabrò, P., Oreto, G., Zijlstra, F., & Valgimigli, M. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv038 · Cited by 86
Généreux, P., Rutledge, D. R., Palmerini, T., Caixeta, A. M., Kedhi, E., Hermiller, J. B., Wang, J., Krucoff, M. W., Jones-McMeans, J. M., Sudhir, K., et al. (2015) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.114.001362 · Cited by 86
Self-citationData monitoring committees: Promoting best practices to address emerging challenges
Fleming, T. R., DeMets, D. L., Roe, M. T., Wittes, J. T., Calis, K. A., Vora, A. N., Meisel, A., Bain, R. P., Konstam, M. A., Pencina, M. J., et al. (2017) · Clinical Trials · doi:10.1177/1740774516688915 · Cited by 86
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
Costa, F., & Valgimigli, M. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1508692 · Cited by 85
Platelets, inflammation and anti-inflammatory effects of antiplatelet drugs in ACS and CAD
Müller, K., Chatterjee, M., Rath, D., & Geisler, T. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-11-0947 · Cited by 90
Nanotechnology in Diagnosis and Treatment of Coronary Artery Disease
Karimi, M., Zare, H., Nik, A. B., Yazdani, N., Hamrang, M., Mohamed, E., Zangabad, P. S., Basri, S. M. M., Bakhtiari, L., & Hamblin, M. R. (2016) · Nanomedicine · doi:10.2217/nnm.16.3 · Cited by 83
Stirred, shaken, or stagnant: What goes on at the blood–biomaterial interface
Reviakine, I., Jung, F., Braune, S., Brash, J. L., Latour, R. A., Gorbet, M., & van Oeveren, W. (2016) · Blood Reviews · doi:10.1016/j.blre.2016.07.003 · Cited by 89
Endothelialization of drug eluting stents and its impact on dual anti-platelet therapy duration
Habib, A., & Finn, A. V. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.12.003 · Cited by 81
Evolution of Coronary Stent Technology and Implications for Duration of Dual Antiplatelet Therapy
Moon, J. Y., Franchi, F., Rollini, F., & Angiolillo, D. J. (2017) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2017.12.004 · Cited by 81
Pei, C., Zhang, Y., Wang, P., Zhang, B., Fang, L., Liu, B., & Meng, S. (2019) · Phytotherapy Research · doi:10.1002/ptr.6217 · Cited by 80
Costa, F., Tijssen, J. G. P., Ariotti, S., Giatti, S., Moscarella, E., Guastaroba, P., Palma, R. D., Andò, G., Oreto, G., Zijlstra, F., et al. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.002524 · Cited by 85
“Antithrombotic therapies after coronary intervention reduce ischemic events but invariably increase bleeding risk, which in turn may adversely affect short- and long-term outcomes.(5,6) International guidelines recommend careful evaluation of both ischemic and bleeding risk based on the patient’s clinical characterist…”
Polymer-Free Biolimus A9-Coated Stents in the Treatment of De Novo Coronary Lesions
da Costa, R. A., Abizaid, A., Mehran, R., Schöfer, J., Schuler, G. C., Hauptmann, K. E., Magalhães, M. A., Parise, H., & Grube, E. (2016) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2015.09.008 · Cited by 80
Zhao, B., Li, Z., Wang, Y., Ma, X., Wang, X., Wang, X., Liu, J., Huang, Y., Zhang, J., Li, L., et al. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.04.005 · Cited by 79
“Absolute difference and 95% CIs of relative risks (RRs) for dichotomous data and Cohen's d for continuous data were used to express the effect size (Cohen, 1988; Mauri et al., 2014; Spencer et al., 2015).”
MethodNatsuaki, M., Morimoto, T., Yamamoto, E., Shiomi, H., Furukawa, Y., Abe, M., Nakao, K., Ishikawa, T., Kawai, K., Yunoki, K., et al. (2015) · Cardiovascular Intervention and Therapeutics · doi:10.1007/s12928-015-0366-9 · Cited by 79
“Considering the increased bleeding events and a signal suggesting increasing mortality [21], systematic implementation of prolonged DAPT would not be appropriate.”
BackgroundExternal Validation of the DAPT Score in a Nationwide Population
Ueda, P., Jernberg, T., James, S. K., Alfredsson, J., Erlinge, D., Ömerovic, E., Persson, J., Ravn‐Fischer, A., Tornvall, P., Svennblad, B., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.06.023 · Cited by 78
Kang, J., & Kim, H.-S. (2018) · Korean Circulation Journal · doi:10.4070/kcj.2018.0166 · Cited by 79
Nusca, A., Viscusi, M. M., Piccirillo, F., Filippis, A. D., Nenna, A., Spadaccio, C., Nappi, F., Chello, C., Mangiacapra, F., Grigioni, F., et al. (2022) · Life · doi:10.3390/life12030393 · Cited by 76
“The DAPT trial showed that long-term treatment with dual antiplatelet therapy (DAPT) reduced the risk of myocardial infarction and stent thrombosis in patients receiving DES at the cost of a raised risk of moderate bleeding [73].”
BackgroundBaber, U., Dangas, G., Chandrasekhar, J., Sartori, S., Steg, P. G., Cohen, D. J., Giustino, G., Ariti, C. A., Witzenbichler, B., Henry, T. D., et al. (2016) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2016.04.009 · Cited by 76
“Our primary intent was to examine mortality risk related to nonfatal CTE and bleeding, as both of these events were either reduced or increased by a prolonged DAPT strategy (6).”
Self-citationDual antiplatelet therapy for secondary prevention of coronary artery disease
Degrauwe, S., Pilgrim, T., Aminian, A., Noble, S., Meier, P., & Iglesias, J. F. (2017) · Open Heart · doi:10.1136/openhrt-2017-000651 · Cited by 85
“Although the DAPT study 25 and two subsequent meta-analyses 31–33 showed that extended DAPT duration beyond 1 year after DES may reduce the risk of MI and ST, it has been associated with increased mortality due to increased risk of non-CV mortality not offset by a reduction in CV mortality.”
BackgroundThe State of the Absorb Bioresorbable Scaffold
Bangalore, S., Bezerra, H. G., Rizik, D. G., Armstrong, E. J., Samuels, B. A., Naidu, S. S., Grines, C. L., Foster, M. T., Choi, J. W., Bertolet, B. D., et al. (2017) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2017.09.041 · Cited by 76
Baber, U., Farkouh, M. E., Arbel, Y., Muntner, P., Dangas, G., Mack, M. J., Hamza, T. H., Mehran, R., & Fuster, V. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw378 · Cited by 76
Kirtane, A. J., Stoler, R., Feldman, R., Neumann, F., Boutis, L., Tahirkheli, N. K., Töelg, R., Othman, I., Stein, B., Choi, J. W., et al. (2021) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.120.010144 · Cited by 79
Self-citationSecemsky, E. A., Shen, C., Schermerhorn, M. L., & Yeh, R. W. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.2738 · Cited by 74
Self-citationAbu‐Assi, E., López-López, A., Salvado, V. G., Diéguez, A. R., Peña, C., Bouzas‐Cruz, N., Raposeiras‐Roubín, S., Abumuaileq, R. R.-Y., García‐Acuña, J. M., & González‐Juanatey, J. R. (2015) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2015.06.015 · Cited by 74
Cannon, C. P., Gropper, S., Bhatt, D. L., Ellis, S. G., Kimura, T., Lip, G. Y. H., Steg, P. G., ten Berg, J. M., Manassie, J., Kreuzer, J., et al. (2016) · Clinical Cardiology · doi:10.1002/clc.22572 · Cited by 79
Self-citationCapodanno, D., & Angiolillo, D. J. (2023) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2022.10.023 · Cited by 76
Averkov, O. V., HARUTYUNYAN, G., Duplyakov, D. V., Константинова, Е. В., Nikulina, N. N., Shakhnovich, R. M., Yavelov, I. S., Yakovlev, A. N., Abugov, S. A., Alekyan, B. G., et al. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6319 · Cited by 77
Clinical evidence for oral antiplatelet therapy in acute coronary syndromes
Wiviott, S. D., & Steg, P. G. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60213-6 · Cited by 76
Self-citationAntithrombotic therapy in diabetes: which, when, and for how long?
Ajjan, R., Kietsiriroje, N., Badimón, L., Vilahur, G., Gorog, D. A., Angiolillo, D. J., Russell, D., Rocca, B., & Storey, R. F. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab128 · Cited by 74
Prevention of stent thrombosis: challenges and solutions
Lotfi, A. S., & Reejhsinghani, R. S. (2015) · Vascular Health and Risk Management · doi:10.2147/vhrm.s43357 · Cited by 71
Antiplatelet drugs: which targets for which treatments?
Gachet, C. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12947 · Cited by 77
Hara, T., Ughi, G. J., McCarthy, J. R., Erdem, S. S., Mauskapf, A., Lyon, S. C., Fard, A. M., Edelman, E. R., Tearney, G. J., & Jaffer, F. A. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv677 · Cited by 71
“Patients remain at risk of stent thrombosis from both bare metal stents (BMS) and drug-eluting stents (DES), despite dual antiplatelet therapy (DAPT).1 Seminal pathology studies have revealed that stents with delayed healing, characterized by incomplete endothelialization and pro-thrombotic fibrin deposition, are at h…”
BackgroundInfluentialManagement of Patients With NSTE-ACS
Rodríguez, F., & Mahaffey, K. W. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.599 · Cited by 80
Gargiulo, G., Windecker, S., da Costa, B. R., Feres, F., Hong, M., Gilard, M., Kim, H.-S., Colombo, A., Bhatt, D. L., Kim, B., et al. (2016) · BMJ · doi:10.1136/bmj.i5483 · Cited by 71
Metadata
- Authors
- Mauri, L., Kereiakes, D. J., Yeh, R. W., Driscoll-Shempp, P., Cutlip, D. E., Steg, P. G., Normand, S.-L. T., Braunwald, E., Wiviott, S. D., Cohen, D. J., Holmes, D. R., Krucoff, M. W., Hermiller, J., Dauerman, H. L., Simon, D. I., Kandzari, D. E., Garratt, K. N., Lee, D. P., Pow, T. K., Ver Lee, P., Rinaldi, M. J., & Massaro, J. M.
- Affiliations
- Brigham and Women's Hospital (US)
- Christ Hospital (US)
- Harvard University (US)
- Beth Israel Deaconess Medical Center (US)
- University of Missouri–Kansas City (US)
- Duke Medical Center (US)
- St Vincent Hospital (US)
- University of Vermont (US)
- University Hospitals Cleveland Medical Center (US)
- Piedmont Atlanta Hospital (US)
- Lenox Hill Hospital (US)
- Stanford University (US)
- Carolinas Healthcare System (US)
- Boston University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-12-04
- Volume
- 371
- Issue
- 23
- Pages
- 2155-2166
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4481318
- OpenAlex
- W2125173296
- Cited by
- 1,928
- References
- 39
- Citations by year
- 2026: 69 · 2025: 75 · 2024: 80 · 2023: 109 · 2022: 125 · 2021: 154 · 2020: 182 · 2019: 150 · 2018: 183 · 2017: 242 · 2016: 288 · 2015: 254 · 2014: 9
- FWCI
- 181.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- BORIS (University Library Bern) (submittedVersion, other-oa)
- Open Access CRIS of the University of Bern
- Funders
- U.S. Food and Drug Administration (1r01fd003870-01, R01 FD003870)
- National Heart, Lung, and Blood Institute (R01HL057506, R37HL057506, K23HL118138)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- dual antiplatelet therapy, drug-eluting stents, coronary stenting, clopidogrel, prasugrel, thienopyridines, aspirin, stent thrombosis, major adverse cardiovascular events, bleeding risk, myocardial infarction, stroke, mortality, periprocedural bleeding, bleeding risk stratification
- MeSH terms
- Prasugrel Hydrochloride, Clopidogrel, Aged, Aspirin, Drug Administration Schedule, Drug Therapy, Combination, Female, Hemorrhage, Humans, Male, Middle Aged, Piperazines, Platelet Aggregation Inhibitors, Thiophenes, Thrombosis, Ticlopidine, Time Factors, Incidence, Myocardial Ischemia, Drug-Eluting Stents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.